• Journal of Oral Medicine and Pain
• /
• 제41권3호
• /
• pp.126-132
• /
• 2016

Purpose: The aims of this study were to analyze the association between inflammatory cytokine and obstructive sleep apnea (OSA), and to evaluate treatment outcome and changes of plasma inflammatory cytokine levels after oral appliance therapy. Methods: Twenty-seven subjects who visited Department of Oral Medicine in Seoul National University Dental Hospital were performed nocturnal polysomnography and analyzed plasma C-reactive protein (CRP), interleukin (IL)-$1{\beta}$, IL-6, IL-10, and tumor necrosis factor (TNF)-${\alpha}$ levels. Each subject was evaluated with Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). The subjects were classified into 12 OSA patients (apnea-hypopnea index [AHI] >5) and 15 control (AHI ${\leq}5$) groups. The OSA group was treated with mandibular advancement device (MAD) for 3 months and re-evaluated nocturnal polysomnography and plasma inflammatory cytokine levels. Results: Plasma TNF-${\alpha}$, IL-10, and IL-6 levels were significantly higher in OSA patients compared to controls. Total AHI showed significant positive correlations with plasma IL-6 and TNF-${\alpha}$ levels. Percentage time of $SpO_2$ <90 and lowest $SpO_2$ were significantly correlated with plasma TNF-${\alpha}$ level. ESS showed significant positive correlation with plasma IL-10 level. Total AHI, percentage time of $SpO_2$ <90, lowest $SpO_2$, and mean $SpO_2$ were significantly improved after the MAD therapy. Plasma TNF-${\alpha}$ level was significantly decreased after MAD therapy. Conclusions: We suggest that MAD therapy is an effective treatment modality for patients with OSA and can decrease plasma cytokine level.

• The Journal of Korean Physical Therapy
• /
• 제9권1호
• /
• pp.157-166
• /
• 1997

The purpose of this study was to determine the effects of laser Irradiation on Human plasma $\beta-endorphin$ levels, by treating with low level helium-neon (He-Ne) and Infrared(lR) laser. The Laser was fixed frequency of 2400Hz by continuous scanning and irradiating time was 8 minutes each point. Blood samples were taken at before, after, after 15min's treatment and Plasma $\beta-endorphin$ was measured by radioimmunoassay. The samples for this study were 6 normal subjects(3male, 3female). The data were analyzed by paired t-test, one-way ANOVA and simple regression. The results of this study were as follows : 1. The human plasma $\beta-endorphin$ levels were noted as significant increase in after-treatment $(22.84{\pm}10.63pg/ml)$ as compared with before-treatment $(16.96{\pm}9.23pg/ml)$ and significant increase in after 15min's $(27.27{\pm}8.81pg/ml)$ as compared with after-treatment (p<0.05). 2. There were no significant changes in plasma g-endorphin levels between male and female. 3. The human plasma $\beta-endorphin$ levels were high associated in between session reliability (p<0.05).

• Clinical and Experimental Pediatrics
• /
• 제61권2호
• /
• pp.37-42
• /
• 2018

Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating disorder that progressively damages systemic organs, resulting in stroke, end-stage renal disease, and death. The traditional treatment for aHUS is mainly plasmapheresis or plasma infusion; however, many children with aHUS will progress to chronic kidney disease despite plasma therapy. Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Currently, several guidelines for aHUS, including the Korean guideline, recommend eculizumab as the first-line therapy in children with aHUS. Moreover, life-long eculizumab therapy is generally recommended. Further studies on discontinuation of eculizumab are needed.

• The Journal of Korean Physical Therapy
• /
• 제16권3호
• /
• pp.22-31
• /
• 2004

The purpose of this study was to demonstrate the effects of silver spike point (SSP) low frequency electrical stimulation on plasma ${\beta}-endorphin$ activities measured by radio- immunoassay from normal volunteer and the effects of ${\beta}-endorphin$ on 5-hydroxytryptamine (5-HT, serotonin)-induced contraction investigated by isometric tension methode in rats. The current of 3 Hz continue type, but not 100 Hz continue type, of SSP low frequency electrical stimulation significantly increased in plasma ${\beta}-endorphin$ from normal volunteer. The endothelial cell-dependent 5-HT-induced contractions were inhibited by ${\beta}-endorphin$ $1{\mu}M$. These results suggest that the ${\beta}-endorphin$ regulates nociceptive-like substance, such as 5-HT, in part and that the SSP low frequency electrical stimulation, specifically current of low frequency of 3 Hz continue type, significantly increases plasma ${\beta}-endorphin$ from normal volunteer.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제32권1호
• /
• pp.77-80
• /
• 2010

Plasma cell myeloma is malignant disease of plasma cell in the bone marrow. Myeloma accounts for about 1% of all cancers. The solitary plasma cellmyeloma is rare tumors and account for less than 10% of plasma cell neoplasm. It is often progress to multiple myeloma at 30-40% despite successful local treatment with surgery and radiation therapy. We are reporting a case of solitary plasma cell myeloma on anterior maxillary region that developed after kidney transplantation and immunosuppressive therapy.

• IMMUNE NETWORK
• /
• 제9권1호
• /
• pp.20-26
• /
• 2009

We previously reported that $IFN-{\gamma}$ producing T cell responses induced by the combined therapy of DNA vaccine and lamivudine for one year are important for the induction of sustained virological response (SVR). However, $IFN-{\gamma}$ production is not sufficient to predict sustained viremia control in chronic hepatitis B (CHB) carriers treated. Methods: Twelve CHB carriers were intramuscularly immunized 12 times at a 4-week interval with 8mg of HBV DNA vaccine during the standard lamivudine treatment (100mg/daily/1 year). The level of cytokines during and after the combined therapy in plasma of all 12 CHB carriers treated was determined by each ELISA kit. Six out of 12 CHB carriers revisited the clinic, and their HBV DNA levels were examined. Results: The combined therapy increased plasma IL-12 and IL-12/p40 ratio during the treatment (baseline vs. peak level: $41.8{\pm}8.3$ vs. $163.1{\pm}29.2\;pg/ml$; p<0.01 and $0.96{\pm}0.25$ vs. $3.58{\pm}0.86$; p<0.01, respectively), and the peak level of plasma IL-12 and IL-12/p40 ratio was evoked at 6 to 10 months during the combined therapy. In particular, CHB carriers with SVR had two and three-fold higher level of the peak plasma IL-12 and plasma IL-12/p40 ratio than non-virological responders (NVRs), respectively ($218.0{\pm}41.4$ vs. $108.1{\pm}28.6\;pg/ml$; p=0.09 and $5.35{\pm}1.38$ vs. $1.80{\pm}0.29$; p<0.05, respectively), while p40 level was consistent during the combined therapy. In addition, there was no significant temporal correlation between the peak IL-12/p40 ratio and the elevation of serum alanine amino-transferase (ALT) in this study, contrast to $IFN-{\alpha}$ therapy which induced peak IL-12 level following ALT flares. Conclusion: Our results indicate that the combined therapy induces the increase of plasma IL-12 and IL-12/p40 ratio, which are associated with long-term SVR in CHB carriers.

• Nuclear Engineering and Technology
• /
• 제52권5호
• /
• pp.1002-1007
• /
• 2020

The purpose of the current study was to evaluate a spectrum formulation set employed to modify the neutron spectrum of D-D fusion neutrons in a IS plasma focus device using GEANT4, MCNPX2.6, and FLUKA codes. The set consists of a moderator, reflector, collimator and filters of fast neutron and gamma radiation, which placed on the path of 2.45 MeV neutron energy. The treated neutrons eliminate cancerous tissue with minimal damage to other healthy tissue in a method called neutron therapy. The system optimized for a total neutron yield of 10⁹ (n/s). The numerical results indicate that the GEANT4 code for the cubic geometry in the Beam Shaping Assembly 3 (BSA3) is the best choice for the energy of epithermal neutrons.

• 대한기계학회:학술대회논문집
• /
• 대한기계학회 2008년도 추계학술대회A
• /
• pp.1539-1542
• /
• 2008

Plasma is 4th state of matters, which consists of electrons, neutral, and ionized particles. In biomedical research, cold plasma, which is generated in atmospheric condition, has been applied to disinfect microorganisms such as bacteria and yeast cells. Because of its low temperature condition, the heat-sensitive medical device can be easily sterilized by the cold plasma treatment. In recent years, the effects of plasma on mammalian cells have arisen as a new issue. Generally, plasma induces intensity dependent necrotic cell death. In this research, we investigate the feasibility of cold plasma treatment for cancer therapy by conducting comparative study of plasma effects on normal and cancer cells. We use THLE-2 (human liver normal cell) and SK-Hep1 (human liver metathetic cancer cell) as our target cells. The needle type of cold plasma is generated by the Helium plasma device. Two types of cells have different onset plasma conditions for the necrosis, which may be explained by difference in electrical properties of these two cell types.

• The Korean Journal of Physiology
• /
• 제10권1호
• /
• pp.67-71
• /
• 1976

Effect of Electro Convulsion Therapy (ECT) on the Human Growth Hormone (HGH) response was observed in 32 cases of various mental illness. The patients were fasting overnight and ECT was induced in the morning by application of $90{\sim}120V$ for a period of $0.1{\sim}0.5\;sec$. In all patients, venous blood samples were taken prior to simultaneously with 1 and 4 hours after the ECT. Plasma was immediately seperated and stored in $-20^{\circ}C$ refrigerator. HGH concentrantion was determined by means of radioimmunoassay Results were as follows: 1. Application of electric current was not followed by a significant change in mean plasma HGH of 52 cases. 2 Increases of plasma HGH following ECT were observed in about half cases showing low initial level but in 20 other cases with high initial level of plasma HGH, reasonable decreases after therapy were not found. 3. Plasma concentration of HGH one hour after application of current were always higher than just after the current. 4. There were no differences between HGH responses to a 1st, 2nd or 5th ECT. 5. Discussions were made on the possible modification of HGH response following ECT by the autoregulatory control mechanism.

• Nutritional Sciences
• /
• 제7권4호
• /
• pp.214-217
• /
• 2004

Dietary intervention and simvastatin is beneficial in the prevention cardiovascular diseases by lowering plasma lipid levels. Endothelial dysfunction is associated with coronary artery disease and its risk factors and is reversed by dietary intervention. It has been suggested that hyperlipidemia contributes to the development of atherosclerosis by increasing inducible nitric oxide synthase (iNOS) expression via intimal thickening. Statins treatment has been found to decrease iNOS expression and atherogenensis in animal models. We hypothesized that dietary intervention and simvastatin therapy could decrease plasma nitric oxide in hypercholesterolemic patients, which would suggest the opportunity for modulation of iNOS expression through the use of statins in a clinical situation. We measured the plasma levels of nitrite and nitrate (NOx) in 19 hyperlipidemia patients. The subjects were under dietary intervention following simvastatin therapy for 12 weeks. As a result, the plasma level of NOx, stable metabolites of nitric oxide (NO), saw a two-fold elevation in hyperlipidemic patients as compared to normal levels. Although 12 weeks of dietary intervention did not lower NOx levels, subsequent 12-week simvastatin (10 mg/day) treatment, along with dietary intervention, lowered NOx levels significantly. This NOx reduction, induced by simvastatin therapy, positively correlated with lowered coronary risk factors (r=0.40, p=0.02). It indicated that simvastatin therapy decreases plasma NOx levels by, perhaps, decreasing iNOS expression or activity leading to the attenuation of the development of neointima.